Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Ugur Sahin, Kathrin U Jansen, Ping Ren, Xuping Xie, Kena A Swanson, Pei-Yong Shi, Chaitanya Kurhade, Jing Zou, Hongjie Xia, Mingru Liu, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Ugur Sahin, Kathrin U Jansen, Ping Ren, Xuping Xie, Kena A Swanson, Pei-Yong Shi
Abstract
Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original Omicron variant BA.1. Here, we report the neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunized Omicron BA.1-infected individuals against Omicron sublineages and "Deltacron" variant (XD). BNT162b2 post-dose 3 immune sera neutralized USA-WA1/2020, Omicron BA.1-, BA.2-, BA.2.12.1-, BA.3-, BA.4/5-, and XD-spike SARS-CoV-2s with geometric mean titres (GMTs) of 1335, 393, 298, 315, 216, 103, and 301, respectively; thus, BA.4/5 SARS-CoV-2 spike variant showed the highest propensity to evade vaccine neutralization compared to the original Omicron variants BA.1. BA.1-convalescent sera neutralized USA-WA1/2020, BA.1-, BA.2-, BA.2.12.1-, BA.3-, BA.4/5-, and Deltacron-spike SARS-CoV-2s with GMTs of 15, 430, 110, 109, 102, 25, and 284, respectively. The unique mutation F486V in the BA.4/5 spike contributes to the increased evasion of antibody neutralization by sublineage BA.4/5. The low neutralization titres of vaccinated sera or convalescent sera from BA.1 infected individuals against the emerging and rapidly spreading Omicron BA.4/5 variants provide important results for consideration in the selection of an updated vaccine in the current Omicron wave.Trial registration: ClinicalTrials.gov; identifier: NCT04368728.
Keywords: BNT162b2 vaccine; Omicron; SARS-CoV-2; neutralization; variants.
Conflict of interest statement
X.X. and P.-Y.S. have filed a patent on the reverse genetic system of SARS-CoV-2. C.K., J.Z., H.X., X.X., and P.-Y.S. received compensation from Pfizer to perform the project. Q.Y., M.C., D.C., K.U.J., and K.A.S. are employees of Pfizer and may hold stock options. K.A.S. and Q.Y. are inventors on a patent application related to RNA-based COVID-19 vaccines. U.S. and A.M. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccines. A.M is an employee of BioNTech and may hold stock options.
Figures
References
- Kurhade C, Zou J, Xia H, et al. . Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022;13:3602.
- Xia H, Zou J, Kurhade C, et al. . Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe. 2022;30:485–488.e3.
- Colson P, Fournier PE, Delerce J, et al. . Culture and identification of a “Deltamicron” SARS-CoV-2 in a three cases cluster in southern France. J Med Virol. 2022;94(8):3739–3749.
- Zou J, Kurhade C, Xia H, et al. . Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. Nat Commun. 2022;13:2956.
- Lyngse FP, Kirkeby C, Halasa T, et al. . Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February 2020 to 1 August 2020. Euro Surveill. 2022;27(6):2001800.
- Peacock TP, Brown JC, Zhou J, et al. . The SARS-CoV-2 variant, omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. BioRxiv. 2022. doi:10.1101/2021.12.31.474653
- Redd AD, Nardin A, Kared H, et al. . Minimal crossover between mutations associated with Omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals. mBio. 2022;13(2):e03617–21.
- Falsey AR, Frenck RW, Walsh EE, et al. . SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385(17):1627–1629.
- Mulligan MJ, Lyke KE, Kitchin N, et al. . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593.
- Walsh EE, Frenck RW, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450.
- Liu Y, Liu J, Xia H, et al. . Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384:1466–1468.
- Xie X, Muruato A, Lokugamage KG, et al. . An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe. 2020;27:841–848.e3.
- Xie X, Liu Y, Liu J, et al. . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27:620–621.
- Xie X, Lokugamage KG, Zhang X, et al. . Engineering SARS-CoV-2 using a reverse genetic system. Nat Protoc. 2021;16:1761–1784.
- Zou J, Xia H, Xie X, et al. . Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat Commun. 2022;13:852.
Source: PubMed